Orgenesis

Orgenesis is a provider of both cell-based therapies and gene-based therapies for the treatment of issues related to oncology, immunology, cariology, orthopedia, endocrinology. Specifically, the company develops therapeutics to treat cancer, genital warts, Covid-19, pancreatitis, liver, kidney and dermatological diseases, psoriasis, osteoarthritis, erectile dysfunction, musculoskeletal diseases, and acute and chronic kidney diseases. Orgenesis uses various technology models to develop its cell therapeutics, ranging from chimeric antigen receptor T cells, T cells, and natural killer cells. The company has commercialized two therapeutics that are used in clinical settings; Kyslecel for treatment of Chronic Pancreatitis and Cartil-S/Chondroseal for osteoarthritis. The company is listed on the Nasdaq and trades under the symbol ORGS.

As of May 2024, the company had five immuno-oncology therapeutics in development, three therapeutics for viral diseases, two therapeutics for metabolic and autoimmune diseases, two therapeutics for vascular and musculoskeletal diseases, and two therapeutics for kidney diseases in various stages of clinical testing.

Key customers and partnerships

Orgenesis formed a joint venture in April 2020 with a spin-off from Liege University in Belgium, RevaTis, (a biotechnology company) to further the development of autologous therapies. Through the partnership, RevaTis would build on its success in developing therapeutics to advance its candidate’s testing to human trials by using Orgenesis’s expertise and technology.

Furthermore, in January 2022, the company partnered with Johns Hopkins to create the Maryland Center for Cell Therapy Manufacturing. The center was developed to manufacture cell and gene therapeutics which could be then used to treat patients being treated at Johns Hopkins.

Orgenesis partnered with the University of California, Davis in June 2023 to boost access to gene and cell therapies in California. Through the partnership, Orgenesis Mobile Processing Units and Labs would be rolled out at multiple locations within the university grounds to provide on-site development and manufacturing of cell and gene therapies to help increase access to such therapies while reducing costs.

In April 2024, the company announced that Orgenesis and Germfree, a modular cleanroom infrastructure and service provider, had signed an asset purchase and strategic partnership agreement. Through the partnership, Germfree would combine its expertise and manufacturing facility environments with Orgenesis’ processes and analytical development capabilities to reduce the production costs of cell and gene therapy products.